Argonautica Private Wealth Management Inc. Raises Stake in Smith & Nephew plc (NYSE:SNN)

Argonautica Private Wealth Management Inc. raised its holdings in shares of Smith & Nephew plc (NYSE:SNN) by 12.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,614 shares of the medical equipment provider’s stock after acquiring an additional 1,307 shares during the period. Argonautica Private Wealth Management Inc.’s holdings in Smith & Nephew were worth $285,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in shares of Smith & Nephew in the 3rd quarter valued at $792,000. Charles Schwab Investment Management Inc. boosted its position in Smith & Nephew by 29.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider’s stock valued at $847,000 after buying an additional 6,164 shares during the period. Stifel Financial Corp bought a new position in shares of Smith & Nephew during the third quarter valued at about $1,258,000. Maverick Capital Ltd. bought a new position in shares of Smith & Nephew during the third quarter valued at about $2,086,000. Finally, Blue Trust Inc. increased its holdings in shares of Smith & Nephew by 26.0% in the fourth quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider’s stock worth $144,000 after buying an additional 1,213 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNN has been the topic of several recent analyst reports. Berenberg Bank cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. StockNews.com lowered shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.

Smith & Nephew Price Performance

SNN opened at $28.09 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The stock has a market capitalization of $12.28 billion, a PE ratio of 13.01, a price-to-earnings-growth ratio of 1.26 and a beta of 0.84. The stock’s 50 day moving average price is $25.11 and its 200-day moving average price is $27.22. Smith & Nephew plc has a 52-week low of $23.65 and a 52-week high of $31.72.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.